Recombinant human activated factor VII in postpartum hemorrhagic shock: The dark side [2]

Intensive Care Medicine

Volumn 34, Issue 1, 2008, Pages 211-212

  Van Veen, E J W ^a   Monteban Kooistra, W E ^a   Meertens, J H J M ^a   Ligtenberg, J J M ^a   Tulleken, J E ^a   Zijlstra, J G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADULT; ANGIOGRAPHY; BLISTER; BLOOD CLOTTING; BOLUS INJECTION; CAPILLARY FLOW; CASE REPORT; CESAREAN SECTION; CYANOSIS; ECHOGRAPHY; FEMALE; FETUS DISTRESS; FOOT AMPUTATION; HEMATOMA; HEMODYNAMICS; HEMORRHAGIC SHOCK; HEMOSTASIS; HUMAN; LETTER; LIMB ISCHEMIA; POSTPARTUM HEMORRHAGE; REPEATED DRUG DOSE; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; VAGINA BLEEDING;

ADULT; FACTOR VIIA; FEMALE; HUMANS; POSTPARTUM PERIOD; SHOCK, HEMORRHAGIC;

EID: 38149137135     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-007-0810-0     Document Type: Letter

References (4)

1. Franchini M, Lippi G, Franchi M (2007) The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. Br J Obstet Gynaecol 114:8-15
2. Haynes J, Laffan M, Plaat F (2007) Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth 16:40-49
3. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM (2006) Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295:293-298
4. Levi M, Peters M, Buller HR (2005) Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33:883-890